November 29, 2017

What the FDA's New Framework Means for Regenerative Therapies


The FDA recently passed a new policy framework governing the development and oversight of regenerative medicine. Attorney Michael Werner discussed these new policies and what they mean for the industry at large on an episode of RARECast.

Duration: 27:20

Related Insights